Efficacy and safety of Saccharomyces boulardii in amebiasis-associated diarrhea in children.

The efficacy and safety of adding Saccharomyces boulardii to antibiotic treatment for amebiasis-associated acute diarrhea in children were assessed in this study. Forty-five children in Group I received only metronidazole per oral for 10 days while 40 patients in Group II received S. boulardii in addition to the same medication. The major outcomes investigated were duration of acute and bloody diarrhea, frequency and consistency of stools, resolution time of the symptoms, and the tolerance and side effects of the treatment regimens. The median duration of acute diarrhea was 5 (1-10) days in Group I and 4.5 (1-10) days in Group II (p=0.965). The median number of stools on follow-up and duration of bloody diarrhea, fever, abdominal pain and vomiting were similar in the two groups. S. boulardii was well tolerated by the children and no side effects were recorded. Addition of S. boulardii to antibiotic treatment of amebiasis-associated acute diarrhea in children does not seem to be more effective than metronidazole treatment alone.

[1]  I. Zakharova,et al.  [Prevention of antibiotic-associated diarrhea in children]. , 2011, Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology.

[2]  H. Szajewska.  Probiotics and prebiotics in pediatrics: where are we now? , 2007, The Turkish journal of pediatrics.

[3]  C. Y. Ooi,et al.  Probiotics in paediatric gastrointestinal diseases , 2007, Journal of paediatrics and child health.

[4]  R. Haque,et al.  Entamoeba histolytica Infection in Children and Protection from Subsequent Amebiasis , 2006, Infection and Immunity.

[5]  L. Mcfarland,et al.  META-ANALYSIS OF PROBIOTICS FOR THE PREVENTION AND TREATMENT OF ACUTE PEDIATRIC DIARRHEA , 2006 .

[6]  Patricia Muñoz,et al.  Saccharomyces cerevisiae fungemia: an emerging infectious disease. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  O. Erdeve,et al.  The probiotic effect of Saccharomyces boulardii in a pediatric age group. , 2004, Journal of tropical pediatrics.

[8]  LeventDoganci,et al.  Accurate diagnosis is essential for amebiasis , 2004 .

[9]  Caryn Bern,et al.  The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. , 2003, Bulletin of the World Health Organization.

[10]  V. Imbert,et al.  Saccharomyces boulardii Interferes with Enterohemorrhagic Escherichia coli-Induced Signaling Pathways in T84 Cells , 2003, Infection and Immunity.

[11]  FariborzMansour-Ghanaei,et al.  Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis , 2003 .

[12]  J. Jacquemin,et al.  Possible Role of Catheters in Saccharomyces boulardii Fungemia , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[13]  U. Singh,et al.  Diagnosis and management of amebiasis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  L. Doğancı,et al.  Overdiagnosis of intestinal amoebosis in Turkey , 1997, The Lancet.

[15]  C. Pothoulakis,et al.  Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum , 1996, Infection and immunity.

[16]  J. Buts,et al.  Saccharomyces boulardii Enhances Rat Intestinal Enzyme Expression by Endoluminal Release of Polyamines , 1994, Pediatric Research.

[17]  R. Haque,et al.  Value of microscopy in the diagnosis of dysentery associated with invasive Entamoeba histolytica. , 1994, Journal of clinical pathology.

[18]  C. Pothoulakis,et al.  Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. , 1993, Gastroenterology.

[19]  K. Plein,et al.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. , 1993, Zeitschrift fur Gastroenterologie.

[20]  T. Butler,et al.  Epidemiologic and clinical features of invasive amebiasis in Bangladesh: a case-control comparison with other diarrheal diseases and postmortem findings. , 1988, The American journal of tropical medicine and hygiene.

[21]  J. Walsh,et al.  Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. , 1986, Reviews of infectious diseases.

[22]  H. Bléhaut,et al.  Moyse Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients * A multicenter , randomized , double-blind placebo-controlled trial , 2022 .